NCT06827431View on ClinicalTrials.gov

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

770

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Ammoxetine

Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.

DRUG

Ammoxetine

Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.

DRUG

Placebo

Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.

DRUG

Sertraline

Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY